Emerging therapies for the treatment of patients with advanced neuroendocrine tumors (Q36866607)

16 August 2017

1 reference

title

Emerging therapies for the treatment of patients with advanced neuroendocrine tumors (English)

1 reference

16 August 2017

Jennifer A Chan

1

1 reference

16 August 2017

Matthew H Kulke

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

253-270

1 reference

The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

An analysis of 8305 cases of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Medical treatment of neuroendocrine gut and pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Diagnostic value of plasma chromogranin A in neuroendocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Hepatic surgery for metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Survival and functional quality of life after resection for hepatic carcinoid metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.253

10.1517/14728214.12.2.253

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference